{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:50:36Z","timestamp":1769521836269,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Screening and early diagnosis of pancreatic cancer (PC) are crucial for improving its prognosis. In the current study, we aimed to evaluate the clinical utility of serum cell migration inducing protein in pancreatic cancer patients (CEMIP). This study was conducted on 50 newly diagnosed pancreatic cancer patients, aged from 49 to 77 years. The study also included 20 patients with benign intestinal diseases, and 20 apparently healthy individuals who were selected as a control group for comparison. Practical work was carried out at Clinical Pathology Department, Assiut University Hospital. All groups were subjected to thorough history taking and clinical evaluation. Radiological data and laboratory tests in addition evaluation level of carcinoembryonic antigen (CEA), cancer antigen 19\u2009\u2212\u20099 (CA19-9) and CEMIP were recorded. Pancreatic cancer group had significantly higher CEA, CA19-9 and CEMIP compared to both benign GIT diseases and control group, with (P-value\u2009&lt;\u20090.001) for each. Late pancreatic cancer group had significantly higher CEA, CA19-9 and CEMIP compared to early pancreatic cancer with (P-value\u2009=\u20090.01). For diagnosis of PC, CEMIP was 95% sensitive and 84% specific, with AUC of 0.86 while CEA was 80% sensitive and 65% specific, with AUC of 0.80 and that of serum CA 19\u2009\u2212\u20099 was 58% sensitive and 69% specific, with AUC of 0.80. For diagnosis of early PC, CEMIP was 90% sensitive and 83% specific, with AUC of 0.72. These results are better than that of serum CEA, which was 75% sensitive and 60% specific, with AUC of 0.52 and that of serum CA 19\u2009\u2212\u20099, which was 60% sensitive and 58% specific, with AUC of 0.56. Serum CEMIP may serve as non-invasive biomarkers for diagnosis of pancreatic cancer patients in comparison to other conventional biomarkers.<\/jats:p>","DOI":"10.1038\/s41598-025-07911-9","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:33:46Z","timestamp":1751524426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of CEMIP in diagnosis of pancreatic carcinoma in comparison with other traditional markers"],"prefix":"10.1038","volume":"15","author":[{"given":"Randa Ahmed El","family":"Zohne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Kamel Mostafa Abo","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omnia Abd El","family":"Moneim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mohamed","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina Mohamed","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soad A.","family":"Eltokhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"5","key":"7911_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel, E. M., Brand, R. E. & Goggins, M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164 (5), 752\u2013765 (2023).","journal-title":"Gastroenterology"},{"issue":"3","key":"7911_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/cancers15030761","volume":"15","author":"G Le Cosquer","year":"2023","unstructured":"Le Cosquer, G. et al. Pancreatic cancer in chronic pancreatitis: pathogenesis and diagnostic approach. Cancers 15 (3), 761 (2023).","journal-title":"Cancers"},{"key":"7911_CR3","doi-asserted-by":"publisher","first-page":"107327482311547","DOI":"10.1177\/10732748231154711","volume":"30","author":"K S\u00f8reide","year":"2023","unstructured":"S\u00f8reide, K., Ismail, W., Roals\u00f8, M., Ghotbi, J. & Zaharia, C. Early diagnosis of pancreatic cancer: clinical premonitions, timely precursor detection and increased curative-intent surgery. Cancer Control. 30, 10732748231154711 (2023).","journal-title":"Cancer Control"},{"key":"7911_CR4","doi-asserted-by":"crossref","unstructured":"Ahmadipour, M. et al. CA19-9 and CEA biosensors in pancreatic cancer. Clin. Chim. Acta, : p. 117788. (2024).","DOI":"10.1016\/j.cca.2024.117788"},{"key":"7911_CR5","doi-asserted-by":"crossref","unstructured":"Sumiyoshi, T. et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. Ann. Surg. Oncol., : pp. 1\u20138. (2024).","DOI":"10.1245\/s10434-024-15221-z"},{"key":"7911_CR6","doi-asserted-by":"publisher","first-page":"e16930","DOI":"10.7717\/peerj.16930","volume":"12","author":"S Guo","year":"2024","unstructured":"Guo, S. et al. The role of CEMIP in cancers and its transcriptional and post-transcriptional regulation. PeerJ 12, e16930 (2024).","journal-title":"PeerJ"},{"issue":"10","key":"7911_CR7","doi-asserted-by":"publisher","first-page":"17156","DOI":"10.18632\/oncotarget.15052","volume":"8","author":"S Kohi","year":"2017","unstructured":"Kohi, S., Sato, N., Koga, A., Matayoshi, N. & Hirata, K. KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. Oncotarget 8 (10), 17156 (2017).","journal-title":"Oncotarget"},{"issue":"12","key":"7911_CR8","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.7150\/jca.19295","volume":"8","author":"L Li","year":"2017","unstructured":"Li, L., Yan, L. H., Manoj, S., Li, Y. & Lu, L. Central role of CEMIP in tumorigenesis and its potential as therapeutic target. J. Cancer. 8 (12), 2238 (2017).","journal-title":"J. Cancer"},{"issue":"1","key":"7911_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41420-018-0099-5","volume":"4","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. Knockdown of KIAA1199 attenuates growth and metastasis of hepatocellular carcinoma. Cell. Death Discovery. 4 (1), 102 (2018).","journal-title":"Cell. Death Discovery"},{"key":"7911_CR10","doi-asserted-by":"crossref","unstructured":"Liu, J., Yan, W., Han, P. & Tian, D. The Emerging Role of KIAA1199 in cancer Development and Therapy138p. 111507 (Biomedicine & Pharmacotherapy, 2021).","DOI":"10.1016\/j.biopha.2021.111507"},{"issue":"20","key":"7911_CR11","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.3390\/cancers14205093","volume":"14","author":"K Domanegg","year":"2022","unstructured":"Domanegg, K., Sleeman, J. P. & Schmaus, A. CEMIP, a promising biomarker that promotes the progression and metastasis of colorectal and other types of cancer. Cancers 14 (20), 5093 (2022).","journal-title":"Cancers"},{"issue":"1","key":"7911_CR12","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41598-018-21823-x","volume":"8","author":"HS Lee","year":"2018","unstructured":"Lee, H. S. et al. Combined use of CEMIP and CA 19\u2009\u2013\u20099 enhances diagnostic accuracy for pancreatic cancer. Sci. Rep. 8 (1), 3383 (2018).","journal-title":"Sci. Rep."},{"issue":"1","key":"7911_CR13","first-page":"61","volume":"18","author":"A Kanno","year":"2018","unstructured":"Kanno, A. et al. Multicenter Study Early Pancreat. cancer Japan Pancreatology, 18(1): 61\u201367. (2018).","journal-title":"Multicenter Study Early Pancreat. cancer Japan Pancreatology"},{"key":"7911_CR14","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1245\/s10434-009-0469-6","volume":"16","author":"S Matsuzaki","year":"2009","unstructured":"Matsuzaki, S. et al. Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer. Ann. Surg. Oncol. 16, 2042\u20132051 (2009).","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"7911_CR15","doi-asserted-by":"publisher","first-page":"e29059","DOI":"10.1371\/journal.pone.0029059","volume":"7","author":"LC LaPointe","year":"2012","unstructured":"LaPointe, L. C. et al. Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing. PLoS One. 7 (1), e29059 (2012).","journal-title":"PLoS One"},{"issue":"18","key":"7911_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/jnci\/djt224","volume":"105","author":"NA Evensen","year":"2013","unstructured":"Evensen, N. A. et al. Unraveling the role of KIAA1199, a novel Endoplasmic reticulum protein, in cancer cell migration. J. Natl Cancer Inst. 105 (18), 1402\u20131416 (2013).","journal-title":"J. Natl Cancer Inst."},{"issue":"2","key":"7911_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/1354750X.2020.1725786","volume":"25","author":"L van Manen","year":"2020","unstructured":"van Manen, L. et al. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers 25 (2), 186\u2013193 (2020).","journal-title":"Biomarkers"},{"key":"7911_CR18","doi-asserted-by":"crossref","unstructured":"Meng, Q. et al. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. OncoTargets and Therapy, 10(null): pp. 4591\u20134598. (2017).","DOI":"10.2147\/OTT.S145708"},{"issue":"5","key":"7911_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.pan.2016.05.007","volume":"16","author":"H Imaoka","year":"2016","unstructured":"Imaoka, H. et al. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. Pancreatology 16 (5), 859\u2013864 (2016).","journal-title":"Pancreatology"},{"issue":"5","key":"7911_CR20","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1097\/SLA.0000000000004148","volume":"275","author":"H Kato","year":"2022","unstructured":"Kato, H. et al. Role of serum carcinoma embryonic antigen (CEA) level in localized pancreatic adenocarcinoma: CEA level before operation is a significant prognostic indicator in patients with locally advanced pancreatic cancer treated with neoadjuvant therapy followed by surgical resection: a retrospective analysis. Ann. Surg. 275 (5), e698\u2013e707 (2022).","journal-title":"Ann. Surg."},{"key":"7911_CR21","doi-asserted-by":"crossref","unstructured":"Esen, E. et al. Can combined use of tumor markers in pancreatic cancer be a solution to short- and long-term consequences? A retrospective study. Medicine, 102(11). (2023).","DOI":"10.1097\/MD.0000000000033325"},{"key":"7911_CR22","doi-asserted-by":"publisher","first-page":"114017","DOI":"10.1016\/j.ab.2020.114017","volume":"613","author":"M Jozghorbani","year":"2021","unstructured":"Jozghorbani, M., Fathi, M., Kazemi, S. H. & Alinejadian, N. Determination of carcinoembryonic antigen as a tumor marker using a novel graphene-based label-free electrochemical immunosensor. Anal. Biochem. 613, 114017 (2021).","journal-title":"Anal. Biochem."},{"issue":"September","key":"7911_CR23","first-page":"1743","volume":"88","author":"A Mohamed","year":"2020","unstructured":"Mohamed, A., Abdelghany, M. E. & Ibrahim, I. The diagnostic value of CA19. 9 in predicting the resectability of pancreatic Cancer. Med. J. Cairo Univ. 88 (September), 1743\u20131751 (2020).","journal-title":"Med. J. Cairo Univ."},{"key":"7911_CR24","doi-asserted-by":"crossref","unstructured":"Kato, H. et al. Role of serum carcinoma embryonic antigen (CEA) level in localized pancreatic adenocarcinoma: CEA level before operation is a significant prognostic Indicator in patients with locally advanced pancreatic Cancer treated with neoadjuvant therapy followed by surgical resection: A retrospective analysis. Ann. Surg., 275(5). (2022).","DOI":"10.1097\/SLA.0000000000004148"},{"issue":"1","key":"7911_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1477-7819-12-333","volume":"12","author":"F Liu","year":"2014","unstructured":"Liu, F., Du, F. & Chen, X. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer. World J. Surg. Oncol. 12 (1), 333 (2014).","journal-title":"World J. Surg. Oncol."},{"issue":"12","key":"7911_CR26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737159.2022.2168191","volume":"22","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. CEMIP as a prognostic biomarker for cancers: a meta- and bioinformatic analysis. Expert Rev. Mol. Diagn. 22 (12), 1107\u20131115 (2022).","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"6","key":"7911_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1136\/jclinpath-2014-202451","volume":"68","author":"D Reitz","year":"2015","unstructured":"Reitz, D. et al. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. J. Clin. Pathol. 68 (6), 427\u2013433 (2015).","journal-title":"J. Clin. Pathol."},{"issue":"7","key":"7911_CR28","first-page":"11683","volume":"8","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int. J. Clin. Exp. Med. 8 (7), 11683 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"2","key":"7911_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mco.2022.2559","volume":"17","author":"E Ermiah","year":"2022","unstructured":"Ermiah, E. et al. Prognostic value of serum CEA and CA19\u20139 levels in pancreatic ductal adenocarcinoma. Mol. Clin. Oncol. 17 (2), 1\u201310 (2022).","journal-title":"Mol. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/s41598-025-25425-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07911-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07911-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07911-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:02:23Z","timestamp":1761598943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07911-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7911"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07911-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-25425-2","URL":"https:\/\/doi.org\/10.1038\/s41598-025-25425-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23729"}}